Product Highlight - Steglatro

Steglatro^TM is the new SGLT2 inhibitor from MSD, with high selectivity on SGLT2 inhibition offering powerful HbA1C reduction. Steglatro^TM is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control¹:
• as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications¹
• in addition to other medicinal products for the treatment of diabetes¹

Significant 1.7% HbA1c reduction for the 5 mg dose after 26 weeks on patients with HbA1c baseline ≥9% adding Steglatro^TM on top of metformin^2,3
Significant 1.7% HbA1c reduction for the 5 mg dose after 26 weeks on patients with HbA1c baseline ≥9% adding Steglatro^TM on top of metformin and sitagliptin^4,5
Steglatro^TM has comparable overall incidence of adverse events to placebo including urinary tract infection, genital mycotic infection and hypovolemia in Asian patients⁶


References:
1. Hong Kong Product Circular (STEGLATRO^TM, MSD)
2. Rosenstock J, et al. Diabetes Obes Metab 2018;20:520-529
3. Data on file, MSD (VERTIS MET)
4. Dagogo-Jack S, et al. Diabetes Obes Metab 2018;20:530-540
5. Data on file, MSD (VERTIS SITA2)
6. Ji, L. et al. Diabetes Obes Metab 2019;21:1474-1482.